PEAK6 Investments’s Blueprint Medicines BPMC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
$1.37M Buy
14,800
+6,200
+72% +$616K ﹤0.01% 1719
2024
Q2
$927K Sell
8,600
-17,500
-67% -$1.75M ﹤0.01% 1882
2024
Q1
$2.48M Buy
26,100
+1,500
+6% +$129K 0.01% 1274
2023
Q4
$2.27M Buy
24,600
+18,300
+290% +$1.19M 0.01% 1416
2023
Q3
$316K Buy
6,300
+3,300
+110% +$176K ﹤0.01% 2743
2023
Q2
$190K Hold
3,000
﹤0.01% 2911
2023
Q1
$135K Buy
+3,000
New +$135K ﹤0.01% 3360
2022
Q3
Sell
-3,000
Closed -$190K 5024
2022
Q2
$190K Buy
+3,000
New +$176K ﹤0.01% 4804

Other funds holding BPMC

PEAK6 Investments's BPMC Position: Q3 2024 in Review

PEAK6 Investments opened a new position in Blueprint Medicines (BPMC) in Q3 2024: 20,893 shares worth $1.93M. The stake represents ﹤0.01% of the portfolio and ranks #1531 among its holdings. This is a return to the name: PEAK6 Investments previously reported a position in BPMC as recently as Q1 2024.

PEAK6 Investments first reported a position in BPMC in Q1 2023 and has held it in 5 quarters since. 319 funds tracked by Wall St. Rank hold BPMC as of Q3 2024.

  • PEAK6 Investments held 20,893 shares of Blueprint Medicines worth $1.93M as of Q3 2024.
  • Blueprint Medicines was a new PEAK6 Investments position in Q3 2024.
  • Blueprint Medicines made up ﹤0.01% of PEAK6 Investments's portfolio in Q3 2024, its #1531 holding.
  • PEAK6 Investments first reported a position in Blueprint Medicines in Q1 2023 and has held it in 5 quarters since.
  • 319 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2024.

Based on PEAK6 Investments's 13F filing for Q3 2024, filed 14 Nov 2024.